Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
SAN DIEGO, Aug. 5, 2015 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (Nasdaq:CNAT), a biotechnology company focused on the development and commercialization of novel medicines to treat liver...
-
SAN DIEGO, July 29, 2015 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (Nasdaq:CNAT), a biotechnology company focused on the development and commercialization of novel medicines to treat liver...
-
SAN DIEGO, June 25, 2015 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (Nasdaq:CNAT) today announced pre-treatment biomarker and histology data from the first 16 patients enrolled in the company's...
-
SAN DIEGO, June 22, 2015 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (Nasdaq:CNAT), a biotechnology company focused on the development and commercialization of novel medicines to treat liver...
-
SAN DIEGO, June 8, 2015 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (Nasdaq:CNAT), a biotechnology company focused on the development and commercialization of novel medicines to treat liver...
-
SAN DIEGO, May 27, 2015 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (Nasdaq:CNAT) today announced the company's scheduled participation in the following investor conferences in...
-
Meeting with FDA Provides Clarity on Initial Emricasan Registration Pathway in NASH Cirrhosis Evaluating Expansion of Registration Strategy to Include NASH Fibrosis SAN DIEGO, May 7, 2015 (GLOBE...
-
SAN DIEGO, April 30, 2015 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (Nasdaq:CNAT), a biotechnology company focused on the development and commercialization of novel medicines to treat liver...
-
Late-Breaker Posters on Results From Emricasan Phase 2 NAFLD/NASH and ACLF Clinical Trials Poster on Safety and Activity Results From Emricasan Phase 1 Organ Impairment Clinical Trials SAN...
-
SAN DIEGO, April 8, 2015 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (Nasdaq:CNAT), a biotechnology company focused on the development and commercialization of novel medicines to treat liver...